A Multi-omics Study of Epithelial Ovarian Cancer

• Conditions: Whole Exome Sequencing; Tumorigenesis; Metabolomics; Epithelial Ovarian Cancer; Tumor Invasiveness; Transcriptomics

• Registration Number: NCT03742856
• Lead Sponsor: Lei Li

Brief Summary

This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-11
• Study First Submitted: 2018-11-09
• Study Start: 2018-11-10
• Study First Submitted QC: 2018-11-13
• Last Update Submitted: 2018-11-13
• Study First Posted: 2018-11-15
• Last Update Posted: 2018-11-15
• Primary Completion: 2020-11-23
• Study Completion: 2020-11-23

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

• Confirmed primary epithelial ovarian cancer
• Signed an approved informed consents
• Feasible for biopsy

Exclusion Criteria

• Not meeting all of the inclusion criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequencies of somatic driving mutations	Two years	The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival	Five years	Progression-free survival between patients with differential expressed multi-omics will be compared.
Frequencies of alteration of RNA expression	Two years	The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes.
Frequencies of alteration of protein expression and signal pathway	Two years	The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes.

Trial Locations

Locations (1)

Lei Li; 🇨🇳 Beijing, Beijing, China